Yenidoğanda İndirekt ve Direkt Hiperbilirübineminin Yönetimi
Özet
Yenidoğan döneminde hiperbilirubinemi, hem fizyolojik adaptasyonun bir parçası olabilen hem de ciddi nörolojik veya hepatobiliyer hastalıkların erken belirtisi olarak karşımıza çıkabilen yaygın bir klinik durumdur. Bu bölümde yenidoğanda indirekt (unkonjuge) ve direkt (konjuge) hiperbilirubinemi güncel kılavuzlar eşliğinde kapsamlı olarak ele alınmıştır. Bilirubin metabolizmasının temel mekanizmaları, fizyolojik ve patolojik sarılık nedenleri, risk faktörleri, klinik değerlendirme basamakları, tarama stratejileri ve laboratuvar yaklaşımları detaylandırılmıştır. İndirekt hiperbilirubinemi açısından fizyolojik sarılık, hemolitik hastalıklar, yetersiz beslenme, enfeksiyonlar ve metabolik nedenler değerlendirilmiş; fototerapi, intravenöz immünglobulin ve değişim transfüzyonu gibi tedavi seçenekleri açıklanmıştır. Direkt hiperbilirubinemi ise neonatal kolestaz bağlamında ele alınarak biliyer atrezi, enfeksiyonlar, metabolik-genetik hastalıklar ve endokrin nedenler açısından sistematik şekilde incelenmiştir. Erken tanı, uygun ayırıcı tanı algoritmaları ve multidisipliner yaklaşımın, kernikterus, kronik karaciğer hastalığı ve uzun dönem morbiditenin önlenmesindeki kritik rolü vurgulanmıştır. Bölüm, yenidoğan sarılığına klinik pratiğe yönelik bütüncül ve rehber temelli bir yaklaşım sunmaktadır.
Neonatal hyperbilirubinemia is one of the most common clinical conditions in newborns and may represent either a physiological adaptation process or an early manifestation of serious neurological and hepatobiliary disorders. This chapter comprehensively reviews unconjugated (indirect) and conjugated (direct) hyperbilirubinemia in neonates in accordance with current evidence-based guidelines. The fundamental mechanisms of bilirubin metabolism, etiologies of physiological and pathological jaundice, risk factors, clinical evaluation, screening strategies, and laboratory diagnostic approaches are systematically discussed. For indirect hyperbilirubinemia, physiological jaundice, hemolytic diseases, inadequate feeding, infections, and metabolic disorders are examined, along with treatment modalities including phototherapy, intravenous immunoglobulin, and exchange transfusion. Direct hyperbilirubinemia is addressed within the framework of neonatal cholestasis, with detailed consideration of biliary atresia, infections, endocrine disorders, and genetic-metabolic diseases. The critical importance of early diagnosis, differential diagnostic algorithms, and multidisciplinary management in preventing kernicterus, chronic liver disease, and long-term morbidity is emphasized. This chapter provides a comprehensive, guideline-based clinical framework for the diagnosis and management of neonatal jaundice.
Referanslar
Çoban A, Kaynak Türkmen M, Gürsoy T. Türk Neonatoloji Derneği Yenidoğan Sarılıklarına Yaklaşım, İzlem ve Tedavi Rehberi 2022 Güncellemesi 2022 [Available from: https://neonatology.org.tr/uploads/content/tanı-tedavi/2_min.pdf.
Hansen T, Bratlid D. Physiology of neonatal unconjugated hyperbilirubinemia. Care of Jaundiced Neonate New York: McGraw-Hill. 2012:65-95.
Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. New England Journal of Medicine. 2008;358(9):920-8.
Sarathy L, Chou JH, Romano-Clarke G, Lerou PH. Bilirubin measurement and phototherapy use after the AAP 2022 newborn hyperbilirubinemia guideline. Pediatrics. 2024;153(4):e2023063323.
Watchko JF. Bilirubin-induced neurotoxicity in the preterm neonate. Clinics in perinatology. 2016;43(2):297-311.
Bhutani VK. Kernicterus as a ‘never-event’: A newborn safety standard? The Indian Journal of Pediatrics. 2005;72(1):53-6.
Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859.
Par EJ, Hughes CA, DeRico P. Neonatal hyperbilirubinemia: evaluation and treatment. American family physician. 2023;107(5):525-34.
Newman J. Re: Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation)–Summary. Paediatr Child Health 2007; 12 (5): 401–7. Paediatrics & Child Health. 2007;12(7):613-.
Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. American family physician. 2014;89(11):873-8.
Anderson NB, Calkins KL. Neonatal indirect hyperbilirubinemia. Neoreviews. 2020;21(11):e749-e60.
Maisels M, Baltz R, Bhutani V, Pediatrics AAo. Clinical Practice Guideline, Subcommittee on Hyperbilirubinemia. Management of the newborn 35 or more weeks of gestation. Pediatrics. 2004;114:297-316.
Bakari A, Wolski AV, Otoo B, et al. Neonatal Jaundice Treatment Versus Recommendations: The Challenge of Treatment Without Rapid Diagnostic Capability. International Journal of Environmental Research and Public Health. 2025;22(7):1032.
Balasubramanian R, Nguyen K, Wells S, Schutzman DL. Effect of the 2022 AAP Guideline for Managing Hyperbilirubinemia in the Newborn. American Journal of Perinatology. 2025.
Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of pediatric gastroenterology and nutrition. 2017;64(1):154-68.
Feldman AG, Sokol RJ, editors. Recent developments in diagnostics and treatment of neonatal cholestasis. Seminars in pediatric surgery; 2020: Elsevier.
BA H. Biliary atresia. Gastroenterol Clin North Am. 2003;32:891-991.
Hopkins PC, Yazigi N, Nylund CM. Incidence of biliary atresia and timing of hepatoportoenterostomy in the United States. The Journal of pediatrics. 2017;187:253-7.
Wolf A, Pohlandt F. Bacterial infection: the main cause of acute cholestasis in newborn infants receiving short‐term parenteral nutrition. Journal of pediatric gastroenterology and nutrition. 1989;8(3):297-303.
Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in neonates with intestinal resection and long‐term parenteral nutrition. Journal of pediatric gastroenterology and nutrition. 1998;27(2):131-7.
Bull LN, Ellmers R, Foskett P, et al. Cholestasis due to USP53 deficiency. Journal of pediatric gastroenterology and nutrition. 2021;72(5):667-73.
Hof WF, de Boer JF, Verkade HJ. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials. Expert Opinion on Emerging Drugs. 2024;29(3):305-20.
[Available from: https://www.uptodate.com/contents/causes-of-cholestasis-in-neonates-and-young infants?search=Causes%20of%20cholestasis%20in%20neonates%20and%20young%20infants&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
